Concentrated, inhalable antibiotic formulation
A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.
1. A method of treatment, comprising:
aerosolizing a liquid composition to create aerosolized particles;
inhaling the aerosolized particles into a patient's lungs;
wherein the liquid composition comprises,
a free, unencapsulated ciprofloxacin in an aqueous solution at a concentration of about 10 mg/ml or more with sodium acetate; and
a liposome-encapsulated ciprofloxacin wherein the liposomes are comprised of cholesterol and hydrogenated soy phosphatidyl-choline.
2. The method of claim 1 , wherein the aerosolized particles have a diameter in a range of from about 2 microns to about 4 microns.
3. The method of claim 1 , wherein the liquid composition has a pH of 5.0 or less.
4. The method of claim 1 , wherein the liquid composition has a pH of 4.0 or less.
5. The method of claim 1 , wherein the liquid composition has a pH of 3.2.
6. The method of claim 1 , wherein the free, unencapsulated ciprofloxacin is in the aqueous solution at a concentration of about 30 mg/mL.
7. The method of claim 1 , wherein the patient is suffering from a lower respiratory tract infection.
8. The method of claim 7 , wherein the lower respiratory tract infection is due to P. aeruginosa.
9. The method of claim 8 , wherein the patient suffers from cystic fibrosis.
10. The method of claim 1 , wherein the liposomes have a diameter within a range of from about 10 nm to about 10 μm and wherein said liposomes further comprise a lipid selected from the group consisting of fatty acids; lysolipids; sphingolipids; phosphatidylcholines; phosphatidylethanolamines; sphingomyelin; glycolipids; glucolipids; glycosphingolipids; phosphatidic acid; palmitic acid; stearic acid; arachidonic acid; oleic acid; lipids bearing sulfonated mono-, di-, oligo- or polysaccharides; lipids with ether and ester-linked fatty acids, polymerized lipids, diacetyl phosphate, stearylamine, cardiolipin, phospholipids with short chain fatty acids of 6 to 8 carbons in length, synthetic phospholipids with asymmetric acyl chains; and lipids bearing a covalently bound polymer.
11. The method of claim 1 , wherein the liposome encapsulated ciprofloxacin is released at a rate of between about 0.1% to 100% per hour with substantially complete release of ciprofloxacin occurring after about 1 to 24 hours.
12. The method of claim 1 , wherein the liposome encapsulated ciprofloxacin is released at a rate of between about 0.5% to 20% per hour with substantially complete release of ciprofloxacin occurring after about 1 to 12 hours.
13. The method of claim 1 , wherein the liposome encapsulated ciprofloxacin is released at a rate of between about 2% to 10% per hour with substantially complete release of ciprofloxacin occurring after about 1 to 6 hours.
14. The method of claim 1 , further comprising administering a therapeutic agent selected from the group consisting of DNase, a mucoregulatory agent, chemicals that up-regulate the chloride ion channel or increase flow of ions across the epithelial surface of cells, including lantibiotics such as duramycin, agents to promote hydration or mucociliary clearance including epithelial sodium channel (ENaC) inhibitors or P2Y2 agonists such as denufosol, a bronchodilator, a steroid, an elastase inhibitor such as Alpha-1 antitrypsin (AAT), N-acetylcysteine, agents that enhance the activity of an anti-infective against biofilm bacteria such as sodium salicylate, gamma interferon, alpha interferon, a fluoroquinolone, an antibiotic, or a fluoroquinolone selected from the group consisting of amifloxacin, cinoxacin, ciprofloxacin, danofloxacin, difloxacin, enoxacin, enrofloxacin, fleroxacin, irloxacin, lomefloxacin, miloxacin, norfloxacin, ofloxacin, pefloxacin, rosoxacin, rufloxacin, sarafloxacin, sparfloxacin, temafloxacin and tosufloxacin or an antibiotic selected from the group of tobramycin, colistin, azithromycin, amikacin, cefaclor (Ceclor), aztreonam, amoxicillin, ceftazidime, cephalexin (Keflex), gentamicin, vancomycin, imipenem, doripenem, piperacillin, minocycline, or erythromycin.
15. A method of treatment, comprising:
aerosolizing a liquid composition to create aerosolized particles;
inhaling the aerosolized particles into a patient's lungs;
wherein the liquid composition comprises,
a free, unencapsulated ciprofloxacin in an aqueous solution at a pH of 4.0 or less at a concentration of about 20 mg/ml or more with sodium acetate; and
a liposome-encapsulated ciprofloxacin wherein the liposomes are comprised of cholesterol and hydrogenated soy phosphatidyl-choline,
wherein the aerosolized particles have a diameter in a range of from about 2 microns to about 4 microns.
16. The method of claim 15 , wherein the liquid composition has a pH of 3.2.
17. The method of claim 15 , wherein the free, unencapsulated ciprofloxacin is in the aqueous solution at a concentration of about 30 mg/mL.
18. The method of claim 15 , wherein the patient is suffering from a lower respiratory tract infection.
19. The method of claim 15 , wherein the liposome encapsulated ciprofloxacin is released at a rate of between about 0.1% to 100% per hour with substantially complete release of ciprofloxacin occurring after about 1 to 24 hours.
20. The method of claim 15 , wherein the liposome encapsulated ciprofloxacin is released at a rate of between about 0.5% to 20% per hour with substantially complete release of ciprofloxacin occurring after about 1 to 12 hours.
21. The method of claim 15 , wherein the liposome encapsulated ciprofloxacin is released at a rate of between about 2% to 10% per hour with substantially complete release of ciprofloxacin occurring after about 1 to 6 hours.